A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients

Inclusion Criteria:

• Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney.
• Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure.

Exclusion Criteria:

• Patient has received or is receiving an organ transplant other than kidney
• Patient has received a kidney transplant from a cadaveric donor >= 60 years of age.